News

The MAA includes clinical and safety data from Savient‘s pivotal Phase 3 studies and the Open Label Extension program of Krystexxa. Savient Pharma CEO John Johnson said they

Thermo Fisher will refurbish all traded-in instruments and donate them to Seeding Labs, an organization that places scientific instrumentation in the academic institutions of developing nations. Thermo Fisher

For the first quarter of 2011, the company has reported a net loss of $12.36m, or $0.17 loss per diluted share, compared to $8.18m or $0.13 per diluted

The company has reported a net income of $211.61m, or $2.64 per diluted share, compared to $100.33m, or $1.35 per diluted share, for the same period last year.

MP0112 is a phase II proprietary therapeutic DARPin protein targeting VEGF under experiment for the treatment of retinal diseases. Under the pact, Molecular Partners and Allergan will jointly

Selexys Pharmaceuticals will recruit around 30 healthy subjects in the trial. The study will investigate the safety and pharmacology of SelG1 prior to advancement into a Phase II

The once-daily tablet roflumilast is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor. Data from four randomized placebo controlled trials have shown that roflumilast reduces exacerbations and improves

Under the agreement, both the parties will jointly work for identifying, characterizing and optimizing new treatments for malaria. The ‘Orthology Malaria’ project aims at developing drug candidates from

For the first quarter of 2011, the company has reported a net income of $351,000, or $0.02 per diluted share, compared to $711,000 or $0.05 per diluted share,